Companies similar to N-LOREM FOUNDATION
Sign up to Download

1-30 of 6,390,767 results

  • www.nlorem.org
  • 2
  • 1
  • 35
Our mission is to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients with nano-rare diseases... Our Mission We provide an..
Relevance: 25.942482
  • isarna-therapeutics.com
  • 1
  • 2
  • 4
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic..
Relevance: 21.03316
  • www.secarna.com
  • 1
  • 3
  • 4
Secarna Pharmaceuticals is the leading independent European antisense drug discovery company with multiple best-in-class antisense therapies in various stages of pre-clinical development addressing high unmet medical needs across several therapeutic..
Relevance: 20.893015
  • vicotx.com
  • 2
  • 1
  • 11
We are a leader in RNA modulation with antisense oligonucleotides focused on genetic neurological disorders..
Relevance: 18.567476
  • www.biopathholdings.com
  • 3
  • 5
  • 13
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company's lead product candidate, prexigebersen..
Relevance: 17.963058
  • www.arthexbiotech.com
  • 1
  • 12
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases... We are investigating antisense RNA compounds to treat diseases with unmet medical needs..
Relevance: 17.414408
  • www.biopathholdings.com
  • 3
  • 5
  • 13
Bio-Path Holdings is actively developing new targets for hematopoietic diseases and solid tumors and collaborates with academic and clinical leaders to build programs in and beyond oncology... Bio-Path is a biotechnology company developing targeted..
Relevance: 17.255114
  • blackswan-pharma.com
  • 1
  • 2
  • 11
We are able to use these highly informative markers to determine disease risk and modification and identify novel drug targets. Our next steps is then to design in-house antisense RNA-based therapeutics for the patient community...
Relevance: 17.123953
  • splisense.com
  • 1
  • 1
  • 8
SpliSense is a clinical stage company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic and pulmonary diseases... Using an innovative approach. SpliSense aims..
Relevance: 16.154778
  • www.alporttreatmentreport.com
This page tracks new and upcoming treatment options for Alport syndrome. What's in development? What's promising? What's available soon? Current topics include bardoxolone, exon-skipping therapy, antisense oligonucleotides, SAR339375 (lademirsen),..
Relevance: 15.842287
  • www.ribotask.com
  • 1
  • 1
Since its founding in 2006, RiboTask has provided science-based services related to synthesis, design, functionality and patents in the field of modified nucleic acids, in particular antisense oligonucleotides and small interfering RNAs (siRNA and..
Relevance: 15.28603
  • paricam.de
  • 2
  • 2
  • 2
PARICAM is an innovative project provider in drug development for the pharmaceutical industry, specialized in inflammatory health care, from Berlin / Germany. The company focuses on transfer of cutting-edge research to unrecognized growing markets in..
Relevance: 14.877059
  • www.smatreatmentreport.com
This page tracks new and upcoming treatment options for spinal muscular atrophy (SMA). What's in development? What's promising? What's available soon? Current topics include gene therapy, onasemnogene abeparvovec (Zolgensma), AAV9-SMN, RG7916,..
Relevance: 14.761846
  • www.gene-tools.com
  • 1
  • 4
  • 13
Gene Tools, LLC produces and markets Morpholino oligos for antisense applications and ancillary products for basic research. We are also engaged in research relating to delivery of Morpholino oligos into cells and use of Morpholino oligos as probes..
Relevance: 14.509198
  • www.n1collaborative.org
  • 1
The N=1 Collaborative is a group of internationally acclaimed doctors, researchers, patients and companies from across the globe who are collectively committed to expanding the field of individualized medicine. With an initial focus on antisense..
Relevance: 14.108385
  • www.bioinformatics-protocols.com
  • 1
The Bioinformatics-Protocols website is intended for use in teaching Biomedical Science and academic research, containing protocols developed by Dr Nat Milton. The protocols available on the site, plus links to associated websites, have been..
Relevance: 13.986024
  • ugisense.com
  • 3
  • 3
  • 6
UGISense is financed by private investors, Lead Discover Center Dortmund and SeedCapital II Dortmund... UGISense AG is a biotech company dedicated to developing new and innovative antisense therapeutic agents in collaboration with partners from the..
Relevance: 13.592593
  • www.roche.com
Spearheading RNA molecule research since 2003, our site in Copenhagen is focused on leading chemistry for targeting any type of transcribed RNA using short synthetic single-strand oligonucleotides. Here, our experts in the field pioneered our core..
Relevance: 13.562892
  • www.ionispharma.com
  • 2
  • 6
  • 48
Akcea is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI™ (inotersen) and WAYLIVRA® (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis' proprietary antisense..
Relevance: 13.208347
  • synthena.com
  • 2
Synthena AG is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its proprietary tricyclo-DNA technology platform..
Relevance: 13.207378
  • www.rnaibase.org
  • 1
Welcome to RNAiBase, a one stop portal for RNAi sequences generation. Presently in its beta testing phase RNAiBase aims to increase its collection of RNAi tools. The RNAiGen tool is currently available and fully functional. Please do feel free to..
Relevance: 13.047816
  • www.atherobcell.eu
  • 1
WP3 will employ the hits from the WP2 analysis to create new validation tools and use them to abate pro-atherogenic subsets and functions of B cells. Our validation strategy relies on the most advanced biotechnology tools in antisense therapy: the..
Relevance: 12.902114
  • www.mjjbio.com
  • 1
  • 1
  • 6
Guangdong Maijinjia Biotechnologies Co., Ltd. (Registered capital of RMB 15.431944 million), established on August 14, 2019,is an innovative technology enterprise for antisense nucleic acid drugs jointly invested by China and Denmark with an..
Relevance: 12.887388
  • www.leo-consulting.com
  • 1
  • 1
  • 1
Specializing in oncology, hematology, autoimmune disease, rheumatology and related clinical fields, LEOconsulting provides competent advice on clinical development of targeted therapies, all with an impressive track record. Areas of expertise include..
Relevance: 12.650612
  • www.pepfect.com
Unlike many other transfection reagents, PepFect is able to transfect nearly 100% of the cell population and efficiently release the complexed oligonucleotides from endosomes, rendering the delivered oligonucleotides active at their respective..
Relevance: 12.581227
  • tesla.jci.tju.edu
  • 2
Both the RNA imaging approach and the virtual reality approach are being applied to the problem of varying levels of MAOA mRNA and D2DR mRNA in certain brain cells that react strongly to cocaine. We are developing mRNA imaging agents to visualize and..
Relevance: 12.394505
  • alloytx.com
  • 1
  • 14
We offer our platforms and services to the entire drug discovery community and are committed to doing whatever it takes to find you the best therapeutics. Our commitment to reinvesting 100% of our revenue into innovation means we are always acquiring..
Relevance: 11.461733
  • www.gene-tools.com
  • 1
  • 10
  • 13
Endo-Porter is a novel peptide* explicitly designed to do what all existing peptide or lipid-based delivery reagents can not: deliver substances into the cytosol of cells by an endocytosis-mediated process that avoids damaging the plasma membrane of..
Relevance: 11.403635
  • www.genecode.com
  • 1
  • 1
  • 10
GeneCode Ltd was founded in 1993 in Tallinn, Estonia. GENECODE is a private Estonian-American-Finnish-Dutch R&D company, developing innovative treatment strategies in neurodegenerative diseases and anti-virals. For neurodegenerative diseases,..
Relevance: 10.194459
  • yorkclinicalresearch.com
  • 2
  • 1
York Clinical Research, LLC is committed to the development of safe and effective pharmaceuticals, biologics, gene modulating agents, and medical devices for the benefit of all mankind. Founded in 2001, York Clinical Research has some 50 past and..
Relevance: 10.159447